Veliparib (ABT-888)

For research use only. Not for use in humans.

目录号:S1004 别名: NSC 737664 中文名称:维利帕尼

Veliparib (ABT-888) Chemical Structure

CAS No. 912444-00-9

Veliparib (ABT-888, NSC 737664)是一种有效的PARP1PARP2抑制剂,无细胞试验中Ki分别为5.2 nM和2.9 nM,对SIRT2没有活性。Veliparib 可增加自噬和凋亡。Phase 3。

规格 价格 库存 购买数量  
RMB 973.01 现货
RMB 1859.13 现货
RMB 3010.72 现货
RMB 5053.23 现货
RMB 8108.1 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Veliparib (ABT-888)发表文献155篇:

产品安全说明书

PARP抑制剂选择性比较

生物活性

产品描述 Veliparib (ABT-888, NSC 737664)是一种有效的PARP1PARP2抑制剂,无细胞试验中Ki分别为5.2 nM和2.9 nM,对SIRT2没有活性。Veliparib 可增加自噬和凋亡。Phase 3。
特性 ABT-888增强常见癌症疗法的效果,比如放射疗法和烷基化剂。
靶点
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
体外研究

ABT-888有效抑制PARP,作用于PARP-1和PARP-2时Ki值分别为5.2和2.9 nM。ABT-888降低肺癌H460细胞中克隆基因的存活率,且抑制DNA修复。[1]ABT-888抑制C41细胞,EC50为2 nM。[2] ABT-888和放射物联用减少肿瘤血管的形成。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 M4LYc2tqdmG|ZTDBd5NigQ>? NV\qcFNTOzBibXnu NUDQbYQxUW6qaXLpeIlwdiCxZjDQRXJROSC5aYToJGVEPTBib3[gNE4xODJizszN M{nDV|E6QDh6N{[w
Jurkat MWrLbY5ie2ViQYPzZZk> NWruTo1jQTZiaB?= M1PZfGROW09? NWG0eXZEUW6qaXLpeIlwdiCxZjDQRXJROSCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4Yh[2WubDD2bYFjcWyrdImge4l1cCCHQ{WwJI9nKDNizszN M2q3[VI{QDVyMUm5
Capan1 MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXtO|IhcA>? M4r0T2ROW09? MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFLSR2EzKGenbnWgcZV1[XSnZDDoeY1idiCFYYDhclEh[2WubIOge4l1cCCLQ{WwJI9nKDN7Lkeg{txO MYqyOFM6QDN6Mx?=
DT40 NIC4N2pEgXSxdH;4bYMhSXO|YYm= MVm3NkBp NXy4eJg4TE2VTx?= NXHtNmgxS3m2b4TvfIlkcXS7IHHnZYlve3RiY3jpZ4tmdiCEUlPBNk1l\W[rY3nlcpQhTFR2MDDj[Yxtew>? NYTMV4xSOjR7MkK1PFc>
ML-1 NFHyb4VCeG:ydH;0bYMhSXO|YYm= NHrYVWwzNjVizszN MmT3NlQhcA>? M3\IO2ROW09? NHzCd|RUgW6ncnfpd5Rq[2GubImg[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXNiaX6gUWwuOSClZXzsdy=> M13YXVI1QDl3MUO1
HCT-116 MljhT4lv[XOnIFHzd4F6 MUewMlUh|ryP MXiyOEBp M37xcnBCWlBiYXP0bZZqfHliZHXjdoVie2W| MWGyN|A2PDJzMx?=
UM-SCC1 Mmi3R5l1d3SxeHnjJGF{e2G7 Mk\kNVAh|ryP MW[yOEBp NV62eItjWmWmdXPld{B1cGViY3XscEB3cWGkaXzpeJk> NUS5fYJGOjF7MUK2NlA>
FaDu MoDGR5l1d3SxeHnjJGF{e2G7 NELSfG4yOCEQvF2= MmLpNlQhcA>? Mo\BVoVlfWOnczD0bIUh[2WubDD2bYFjcWyrdIm= MUmyNVkyOjZ{MB?=
PC-3 Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXz5e5ZvOTBizszN MYPJcoR2[2W|IHGgd4lodmmoaXPhcpQhcW6qaXLpeIlwdiCrbjDjc4xwdnliZn;ycYF1cW:wwrC= M4nyZ|IyPTdzOUGy
EoL-1-cell NWrDUoRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTLXWZKSzVyPUGuNFc6QCEQvF2= MmLKV2FPT0WU
NCI-SNU-5 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjUTWM2OD1|LkGyPFQyKM7:TR?= Mnm5V2FPT0WU
BV-173 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LSfWlEPTB;NT60OVQxQSEQvF2= NV\qU3FCW0GQR1XS
HCC1806 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfZdVE2UUN3ME21Mlc2OTd|IN88US=> NIHRSoxUSU6JRWK=
COLO-680 M3zqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFr2NJFKSzVyPU[uNlE1ODZizszN NE[1cHRUSU6JRWK=
HCC2218 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrh[G5KSzVyPUeuO|k4ODRizszN NY\lNZYzW0GQR1XS
SK-MEL-24 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;ZNWlnUUN3ME23MlgyQTJ2IN88US=> NFXRXWhUSU6JRWK=
NCI-H720 NHLEPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRThwNEO2NFMh|ryP Mn\IV2FPT0WU
KASUMI-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXrWoRnUUN3ME24Mlg6OjZ4IN88US=> M{fiUXNCVkeHUh?=
HAL-01 NF3ITGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTlwOEi2NkDPxE1? NWDVRlY6W0GQR1XS
CAL-33 M1n1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFyLkSzOEDPxE1? NXq1bIRlW0GQR1XS
SK-MEL-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\rSnNKSzVyPUGyMlQ3PjNizszN MVfTRW5ITVJ?
Ramos-2G6-4C10 NYrPPZJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXRTWM2OD1zMj60O|UzKM7:TR?= MUDTRW5ITVJ?
KY821 M3ywdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z1TWlEPTB;MUKuOFg2KM7:TR?= MkXQV2FPT0WU
HEC-1 NVrCSXlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnP3TWM2OD1zMj65NVk3KM7:TR?= MmPzV2FPT0WU
SK-NEP-1 NGfzV5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XXUWlEPTB;MUOuNVY3KM7:TR?= MX\TRW5ITVJ?
MN-60 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG5XnE6UUN3ME2xN{42Ozh7IN88US=> NH7Ud|FUSU6JRWK=
DU-145 M2X0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF|LkmwOVMh|ryP NEftZ5VUSU6JRWK=
EW-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPjTWM2OD1zND61OVY2KM7:TR?= NFzUUpdUSU6JRWK=
OS-RC-2 M3\KOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF3Lkm1PFkh|ryP MUPTRW5ITVJ?
RPMI-8226 MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfITIN3UUN3ME2xOk4zODR{IN88US=> MojnV2FPT0WU
ChaGo-K-1 M1\GTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTF4LkWzNlUh|ryP NIHOU3pUSU6JRWK=
DEL NXPEbFFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjLTWM2OD1zNj62O|E4KM7:TR?= NXzld4VuW0GQR1XS
GP5d Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HJd2lEPTB;MUeuNFU{KM7:TR?= M3jnRnNCVkeHUh?=
COLO-668 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTF5Lk[yPVQh|ryP NX7tbXY1W0GQR1XS
H9 NVK5XGVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3ZTWM2OD1zOD6yPFM{KM7:TR?= M3vRdnNCVkeHUh?=
NKM-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF6LkWxNVkh|ryP NVX5cW5IW0GQR1XS
KYSE-150 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nWTGlEPTB;MUiuPVk5PiEQvF2= NV7HUnFWW0GQR1XS
Daoy Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nPemlEPTB;MUmuOVY1QSEQvF2= NWTHWJR{W0GQR1XS
ECC10 M1PQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HpfmlEPTB;MkCuO|Q2PSEQvF2= M1HEPXNCVkeHUh?=
A388 M{Wxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJzLkmwPVEh|ryP MUPTRW5ITVJ?
MHH-NB-11 MmGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkS3TWM2OD1{Mz6xN|Y{KM7:TR?= M3;OZXNCVkeHUh?=
HCC1937 NYLwW2hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3K4TmlEPTB;MkSuO|Q3KM7:TR?= NGPOSHpUSU6JRWK=
TGBC11TKB NFfpTYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPXSFRKSzVyPUK1MlY5PjNizszN NXX4ZXpvW0GQR1XS
CTV-1 M1jjXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTnVFk2UUN3ME2yOU45QTZ7IN88US=> M4fT[HNCVkeHUh?=
NCI-H2029 NWW5R3U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rXVmlEPTB;Mk[uOFI{QCEQvF2= NV;zNpM4W0GQR1XS
HLE MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJ5LkC1OEDPxE1? MUHTRW5ITVJ?
NCI-H1693 M3Pue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP6Tno3UUN3ME2yO{4zQDl6IN88US=> MYHTRW5ITVJ?
HCC70 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXq0N2pMUUN3ME2yO{44OjR4IN88US=> M{nsNnNCVkeHUh?=
BEN MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonSTWM2OD1{Nz65OVY3KM7:TR?= M{jWdXNCVkeHUh?=
LB771 NE\SU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPHVFFKSzVyPUK4Mlg{PzNizszN NFXSWHZUSU6JRWK=
697 M{TEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Pm[GlEPTB;MkmuNFI{PSEQvF2= MXLTRW5ITVJ?
LU-139 NH7D[Y1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zNS2lEPTB;MkmuN|c1QCEQvF2= NFTEcINUSU6JRWK=
EW-13 MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3DbYZKSzVyPUK5MlM5OTRizszN M3zvb3NCVkeHUh?=
MOLT-13 Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJ7LkO4NVQh|ryP NEm1clhUSU6JRWK=
L-363 NF7ZW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\4TWM2OD1{OT60O|k5KM7:TR?= M4PXWHNCVkeHUh?=
EM-2 NYrIcI5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV74N3VOUUN3ME2yPU41QTBzIN88US=> NHi5S2JUSU6JRWK=
RS4-11 NHLOOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr2XYM1UUN3ME2zNE41OjRzIN88US=> MXnTRW5ITVJ?
A2780 Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzOVYpKSzVyPUOwMlc1PTdizszN NGPGd|FUSU6JRWK=
KU812 M3vnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTN{LkO2OFIh|ryP M1KzS3NCVkeHUh?=
COLO-684 NHnsVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVq1bZpXUUN3ME2zN{4{PTl7IN88US=> NFi3XoFUSU6JRWK=
MFE-280 NVvYWm9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;Qd|lKSzVyPUOzMlM5QDlizszN NYXkTnB4W0GQR1XS
KG-1 NEHOTFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTN|Lk[wNFEh|ryP M4XSRnNCVkeHUh?=
JVM-3 NWfl[G1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XIXWlEPTB;M{WuOVg3QCEQvF2= MWPTRW5ITVJ?
MV-4-11 M1HuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXqNnZ[UUN3ME2zOU45PDl7IN88US=> MXHTRW5ITVJ?
LAMA-84 NVSxTpYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TYfGlEPTB;M{[uO|M1PSEQvF2= NETU[ZJUSU6JRWK=
MOLT-16 MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XVbWlEPTB;M{[uPVUzKM7:TR?= MmHrV2FPT0WU
H4 Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrwUXlQUUN3ME2zO{42PjdizszN NVHJXotbW0GQR1XS
T47D M2O4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PJc2lEPTB;M{euO|AyQCEQvF2= NFzjNVNUSU6JRWK=
CAL-54 NI\WR|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPSfmZKSzVyPUO3Mlk3PiEQvF2= NXn0VJhFW0GQR1XS
SW982 M4XEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHjTWM2OD1|OD6wPVk5KM7:TR?= NVLBNZBSW0GQR1XS
IGROV-1 M3vreGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTN7LkOzNFQh|ryP NYDzSpJiW0GQR1XS
NB14 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTRyLkewN|Eh|ryP M3HVVnNCVkeHUh?=
HCC1187 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\FPIFKSzVyPUSxMlI4PzFizszN M334cnNCVkeHUh?=
SBC-1 Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13WPGlEPTB;NEGuN|A3OyEQvF2= Mnm5V2FPT0WU
KARPAS-45 M4\N[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTRzLkS4NVgh|ryP M3HVfnNCVkeHUh?=
MOLT-4 M2XzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rwWGlEPTB;NEKuNlU{QCEQvF2= Mny4V2FPT0WU
JVM-2 NXPafZY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLKSldKSzVyPUSyMlkzODdizszN M3fRbHNCVkeHUh?=
A4-Fuk MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrR[JNmUUN3ME20N{42PjlzIN88US=> Mn;ZV2FPT0WU
MDA-MB-361 M3WxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnETWM2OD12Mz64OFE1KM7:TR?= NFn0So5USU6JRWK=
BALL-1 MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETqZYVKSzVyPUSzMlk2OzJizszN NWPmUVM6W0GQR1XS
T98G MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjhTWM2OD12ND64OVE4KM7:TR?= NGn0fGRUSU6JRWK=
Mo-T M{nHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PYeGlEPTB;NEWuOlM5QSEQvF2= NV\vcYpiW0GQR1XS
MHH-PREB-1 NUDT[3hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PNVWlEPTB;NEWuO|U5PSEQvF2= NH3OO4JUSU6JRWK=
ALL-PO NXLBN21CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIW4OWFKSzVyPUS3MlM4QTFizszN MmnVV2FPT0WU
NCI-H510A M{PzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTR5LkmwN|Qh|ryP M1\WfHNCVkeHUh?=
ML-2 NFzNPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTR7Lke4OVYh|ryP NUTPUW8{W0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-STAT3 / STAT3 / p-AKT(S473) / p-AKT(T308) / p-ERK / p-p38; 

PubMed: 22678161     


Effects of AG-014699, AZD-2281, ABT-888, or BSI-201 on the phosphorylation status of Stat3, Akt, ERK, and p38 in MDA-MB-468, MDA-MB-231, and Cal-51 cells after 72 h of treatment

22678161
Immunofluorescence
HuR; 

PubMed: 28687616     


Immunofluorescent images of HuR (green) in MIA PaCa-2 cells treated with PARPi for 12hr. Nuclei were stained with DAPI. Magnification 40X.

BRCA1; 

PubMed: 21917757     


Effects of ABT-888 and/or bortezomib on BRCA1 and RAD51 foci formation. BRCA1 and RAD1 foci induced by ABT-888 were completely resolved in cells cotreated with bortezomib. Image acquisition was performed with an epifluorescence microscope (BX51; Olympus) and multispectral color camera (Nuance FX; CRi) with a 60× or 100× magnification lens and oil immersion.

28687616 21917757
Growth inhibition assay
Cell viability (TNBC cell lines); 

PubMed: 27880910     


BRCA-proficient TNBC cell lines were treated with veliparib in the absence and presence of dinaciclib, demonstrating reduced IC50 values in the presence of dinaciclib.

Cell viability (melanoma cells); 

PubMed: 29956724     


Dose-dependent inhibitory effect of ABT-888 on melanoma cell proliferation. Human melanoma cell lines were exposed to diluents (control; CTRL) or increasing concentrations of ABT-888 for 72 h and their viability was assessed by MTT assay. Absorbance was detected at 540 nm with a microplate reader and data were expressed as a percentage of the CTRL. Data are the means ± SD of 3 experiments performed in triplicate. Statistical significance was calculated against the CTRL (*P<0.05; **P<0.01).

27880910 29956724
体内研究 ABT-888推迟NCI-H460 移植瘤模型的肿瘤生长。ABT-888在B16F10 和9L 移植瘤模型中抑制PARP,从而增强temozolomide的抗癌活性。[1]ABT-888和其他细胞毒素药剂联用作用于MX-1移植瘤模型时显示出强抗癌效力。[2]在A375和 Colo829移植瘤模型中按肿瘤大小,每千克分别加3和12.5 mg ABT-888,可以看到肿瘤内95%以上PAR被抑制。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

体外PARP实验:

在含有50 mM Tris (pH 为8.0), 1 mM DTT,和 4 mM MgCl2的缓冲溶液中进行酶活性测定。PARP反应包含1.5 μM [3H]-NAD+ (1.6 μCi/mmol), 200 nM 生物素组蛋白 H1, 200 nM slDNA,及1 nM PARP-1或4 nM PARP-2酶。在加有100 μL 反应液的 96孔板上进行SPA检测。在50 μL含有PARP和DNA的2×酶液混合物中加入50 μL 2×NAD+基底混合物,反应开始。加入150 μL 1.5 mM 苯甲酰胺反应停止。170uL反应终止液转移到链霉亲和素包被的闪熔镀层上,温育1小时,用微型板块闪烁计数器计数。
细胞实验:[2]
- 合并
  • Cell lines: C41细胞
  • Concentrations: 10 μM 左右
  • Incubation Time: 0.5小时
  • Method: 在96孔板上用ABT-888处理C41细胞0.5小时。用1 mM H2O2破坏DNA10分钟,PARP被激活。用冰冻的PBS冲洗细胞,然后用预冷的甲醇/丙酮(按7:3比例混合)在−20oC下固定10 分钟。风干后,用PBS再溶解,然后用溶有5%脱脂奶粉的PBS- Tween封闭液(0.05%)在室温下阻断0.5小时。细胞和PAR抗体按1:50比例在封闭液中室温下温育1小时,然后用PBS-Tween-20冲洗5分钟,然后加入荧光素-5(6)-异硫氰酸酯 (FITC)-联用的二抗和1μg/mL DAPI封闭液中室温下温育1小时。PBS-Tween-20冲洗5分钟后,用荧光微型版计数器分析数据。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 携带NCI-H460, H460, B16F10和9L移植瘤的C57BL/6鼠
  • Dosages: 25或3.125 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
0.5% methylcellulose+0.2% Tween 80
5 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 244.29
化学式

C13H16N4O

CAS号 912444-00-9
储存条件 粉状
溶于溶剂
别名 NSC 737664

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03044795 Withdrawn Drug: Veliparib Cancer University Medical Center Groningen|AbbVie|Dutch Cancer Society November 2019 Phase 2
NCT02723864 Active not recruiting Drug: Veliparib + VX-970 + Cisplatin Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9 2017 Phase 1
NCT02483104 Completed Drug: veliparib|Drug: carboplatin|Drug: paclitaxel Ovarian Cancer AbbVie July 2015 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

相关PARP产品

Tags: 购买Veliparib (ABT-888) | Veliparib (ABT-888)供应商 | 采购Veliparib (ABT-888) | Veliparib (ABT-888)价格 | Veliparib (ABT-888)生产 | 订购Veliparib (ABT-888) | Veliparib (ABT-888)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID